Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis

SRC: A Century of Science Brought to the Clinic

(2015) Alexey Aleshin et al.   NEOPLASIA

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

(2011) R. S. Finn et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors

(2010) Simon A. Joosse et al.   GENES CHROMOSOMES & CANCER

The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib Treatment

(2010) Jan Zietsch et al.   PLoS One

Chromosomal changes in aggressive breast cancers with basal-like features

(2009) Wayne Yu et al.   CANCER GENETICS AND CYTOGENETICS

Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors

(2009) Tea Blom et al.   JOURNAL OF NEURO-ONCOLOGY

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

(2008) Jiyoung Rhee et al.   BMC CANCER

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

(2008) N. Personeni et al.   CLINICAL CANCER RESEARCH

IncreasedEGFRGene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy

(2008) Fred R. Hirsch et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY